



It's right on the tip of your tongue

Learn about a research study evaluating an investigational oral drug in individuals with Alzheimer's disease who have difficulty thinking and performing day-to-day activities.



About the LIGHTWAVE Study

The clinical research study lasts up to 20 weeks, with up to 7 visits to the study site and 2 phone check-ins. Additionally, there will be assessments done using a mobile device between visits. The investigational drug is a capsule taken by mouth once a day.

The safety and efficacy of the investigational oral drug have not been established. There is no guarantee that the outcome of studies will result in approval by a health authority.

How Do I Qualify?

You may be eligible to participate if you:

- Are 50 to 80 years of age
- Have been diagnosed with mild cognitive impairment or mild dementia due to Alzheimer's disease (a study doctor can evaluate you if you haven't been diagnosed)
- Are able to walk*
- Have a study partner willing to assist with study activities and come to study visits

*Canes and walkers are permitted; wheelchairs are not.

A study doctor can discuss additional eligibility requirements with you.

Your safety is the highest priority while participating. If you have questions or concerns at any point throughout the clinical research study, please speak to a study staff member. [The study staff can also tell you about their specific COVID-19 safety protocols.]

Your participation in the LIGHTWAVE Study is completely voluntary. If you decide to participate in this clinical research study, you are free to withdraw at any time, for any reason, without any penalty or effect on your medical care. Talk to your doctor if you have any questions about Alzheimer's disease or its symptoms, or about participating in this trial.

If You Qualify and Decide to Participate:

- A study doctor will closely monitor you, your symptoms, and your overall health
- All study-related procedures and the investigational oral drug will be provided at no cost
- Transportation assistance may be available, if needed

Learn more about the LIGHTWAVE Study

Kaden Appleberry
Kaden.Appleberry@axiomclinical.com
(813)353-9613 Ext 8

©2023 Sage Therapeutics, Inc. All Rights Reserved. SAGE THERAPEUTICS and the SAGE THERAPEUTICS logo are registered trademarks of Sage Therapeutics, Inc. LIGHTWAVE STUDY and the LIGHTWAVE STUDY logo are trademarks of Sage Therapeutics, Inc. MRC-718-00312 [02/23]
Patient Flyer_LIGHTWAVE_V1_09FEB2023

